The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the country’s medicine indicated specifically for adults with moderate to ...